



Claims:

1. A method of treating ADHD in a mammal in need thereof comprising administering an $\alpha 7$ nAChR full agonist over an effective therapeutic interval with an effective amount of a monoamine reuptake inhibitor or an effective amount of a psychostimulant, or an effective amount of a monoamine reuptake inhibitor and an effective amount of a psychostimulant.
2. The method of claim 1, wherein the monoamine reuptake inhibitor is desipramine (Norpramin), nortriptyline, atomoxetine (Strattera), reboxetine, fluoxetine (Prozac), tomoxetine, bupropion (Wellbutrin), and modafonil (Provigil), provided that the monoamine reuptake inhibitor is present, and wherein the psychostimulant is methylphenidate (Ritalin), dextroamphetamine (Dexedrine), amphetamine (Adderall), and pemoline, provided that the psychostimulant is present.
3. The method of claim 1, wherein the psychostimulant is methylphenidate (Ritalin), dextroamphetamine (Dexedrine), amphetamine (Adderall), and pemoline.
4. The method of claim 1, wherein the agonist is a compound of formula I:



Formula I

wherein Azabicyclo is



wherein X is O, or S;

R_0 is H, lower alkyl, substituted lower alkyl, or lower haloalkyl;

Each R_1 is H, alkyl, cycloalkyl, haloalkyl, substituted phenyl, or substituted naphthyl;

Each R_2 is independently F, Cl, Br, I, alkyl, substituted alkyl, haloalkyl, cycloalkyl, aryl, or R_2 is absent provided that k_{1-2} , k_{1-6} , k_2 , k_5 , k_6 , or k_7 is 0;

k_{1-2} is 0 or 1;

k_{1-6} is 0 or 1, provided that the sum of k_{1-2} and k_{1-6} is one;

k_2 is 0 or 1;

k_5 is 0, 1, or 2;

k_6 is 0, 1, or 2;


k_7 is 0 or 1;

R_{2-3} is H, F, Cl, Br, I, alkyl, haloalkyl, substituted alkyl, cycloalkyl, or aryl;


Each R_3 is independently H, alkyl, or substituted alkyl;

R_4 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, -NH₂, -NH(alkyl), or -N(alkyl)₂;


R_5 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of -O-, =N-, -N(R₁₀)-, and -S-, and having 0-1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I, or R_5 is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring and having the formula



wherein L_1 is O, S, or NR₁₀,



wherein L is CR₁₂ or N, L_2 and L_3 are independently selected from CR₁₂, C(R₁₂)₂, O, S, N, or NR₁₀, provided that both L_2 and L_3 are not simultaneously O, simultaneously S, or simultaneously O and S, or



wherein L is CR₁₂ or N, and L₂ and L₃ are independently selected from CR₁₂, O, S, N, or NR₁₀, and each 9-membered fused-ring moiety having 0-1 substituent selected from R₉ and further having 0-3 substituent(s) independently selected from F, Cl, Br, or I, wherein the R₅ moiety attaches to other substituents as defined in formula I at any position as valency allows;

R₆ is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from R₉ and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R₆ is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R₉ and 0-3 substituent(s) independently selected from F, Cl, Br, or I, wherein the R₆ moiety attaches to other substituents as defined in formula I at any position as valency allows;

R₇ is alkyl, substituted alkyl, haloalkyl, -OR₁₁, -CN, -NO₂, -N(R₈)₂;

Each R₈ is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R₁₃, cycloalkyl substituted with 1 substituent selected from R₁₃, heterocycloalkyl substituted with 1 substituent selected from R₁₃, haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted phenyl;

R₉ is alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, -OR₁₄, -SR₁₄, -N(R₁₄)₂, -C(O)R₁₄, -C(O)N(R₁₄)₂, -CN, -NR₁₄C(O)R₁₄, -S(O)₂N(R₁₄)₂, -NR₁₄S(O)₂R₁₄, -NO₂, alkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R₁₃, cycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R₁₃, or heterocycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R₁₃;

R₁₀ is H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 1 substituent selected from R₇ and further having 0-3 substituents independently selected from F, Cl, Br, or I;


Each R₁₁ is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

Each R_{12} is independently H, F, Cl, Br, I, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -CN, -NO₂, -OR₁₄, -SR₁₄, -N(R₁₄)₂, -C(O)R₁₄, -C(O)N(R₁₄)₂, -NR₁₄C(O)R₁₄, -S(O)₂N(R₁₄)₂, -NR₁₄S(O)₂RR₁₄, or a bond
 5 directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that where valency allows the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -OR₁₄, -SR₁₄,
 10 -N(R₁₄)₂, -C(O)R₁₄, -NO₂, -C(O)N(R₁₄)₂, -CN, -NR₁₄C(O)R₁₄, -S(O)₂N(R₁₄)₂, or -NR₁₄S(O)₂R₁₄, and further provided that the fused-ring moiety has 0-3 substituent(s) selected from F, Cl, Br, or I;

R_{13} is -OR₁₄, -SR₁₄, -N(R₁₄)₂, -C(O)R₁₄, -C(O)N(R₁₄)₂, -CN, -CF₃, -NR₁₄C(O)R₁₄, -S(O)₂N(R₁₄)₂, -NR₁₄S(O)₂R₁₄, or -NO₂;

15 Each R_{14} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

wherein W is (A):



20 wherein R_{A-1a} is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, aryl, -R₅, R₆, -OR_{A-3}, -OR_{A-4}, -SR_{A-3}, F, Cl, Br, I, -N(R_{A-3})₂,
 -N(R_{A-5})₂, -C(O)R_{A-3}, -C(O)R_{A-5}, -CN, -C(O)N(R_{A-3})₂, -C(O)N(R_{A-6})₂,
 25 -NR_{A-3}C(O)R_{A-3}, -S(O)R_{A-3}, -OS(O)₂R_{A-3}, -NR_{A-3}S(O)₂R_{A-3}, -NO₂, and -N(H)C(O)N(H)R_{A-3};

R_{A-1b} is -O-R_{A-3}, -S-R_{A-3}, -S(O)-R_{A-3}, -C(O)-R_{A-7}, and alkyl substituted on the ω carbon with R_{A-7};

Each R_{A-3} is independently selected from H, alkyl, haloalkyl, substituted alkyl,
 30 cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, halo-heterocycloalkyl, substituted heterocycloalkyl, R₅, R₆, phenyl, or substituted phenyl;

R_{A-4} is selected from cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, or substituted heterocycloalkyl;


Each R_{A-5} is independently selected from cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5 , R_6 , phenyl, or substituted phenyl;

Each R_{A-6} is independently selected from alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5 , R_6 , phenyl, or substituted phenyl;

R_{A-7} is selected from aryl, R_5 , or R_6 ;

10

wherein W is (B):



wherein B^0 is -O-, -S-, or -N(R_{B-0})-;

B^1 and B^2 are independently selected from =N-, or =C(R_{B-1})-;

B^3 is =N-, or =CH-, provided that when both B^1 and B^2 are =C(R_{B-1})- and B^3 is =CH-, only one =C(R_{B-1})- can be =CH-, and further provided that when B^0 is -O-, B^2 is =C(R_{B-1})- and B^3 is =C(H)-, B^1 cannot be =N-,

R_{B-0} is H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, limited substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, or aryl, and provided that when B is (B-2) and B^3 is =N- and B^0 is N(R_{B-0}), R_{B-0} cannot be phenyl or substituted phenyl;

R_{B-1} is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, limited substituted alkyl, limited substituted alkenyl, limited substituted alkynyl, aryl, -OR_{B-2}, -OR_{B-3}, -SR_{B-2}, -SR_{B-3}, F, Cl, Br, I, -N(R_{B-2})₂, -N(R_{B-3})₂, -C(O)R_{B-2}, -C(O)R_{B-3}, -C(O)N(R_{B-2})₂, -C(O)N(R_{B-3})₂, -CN, -NR_{B-2}C(O)R_{B-4}, -S(O)₂N(R_{B-2})₂, -OS(O)₂R_{B-4}, -S(O)₂R_{B-2}, -S(O)₂R_{B-3}, -NR_{B-2}S(O)₂R_{B-2}, -N(H)C(O)N(H)R_{B-2}, -NO₂, R_5 , and R_6 ;

Each R_{B-2} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5 , R_6 , phenyl, or substituted phenyl;

Each R_{B-3} is independently H, alkyl, haloalkyl, limited substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl;

R_{B-4} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

wherein W is (C):

(C) is a six-membered heterocyclic ring system having 1-2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six-six-fused-ring system, and further having 1-2 substituents independently selected from R_{C-1} ;

Each R_{C-1} is independently H, F, Cl, Br, I, alkyl, haloalkyl, substituted alkyl, alkenyl, haloalkenyl, substituted alkenyl, alkynyl, haloalkynyl, substituted alkynyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, substituted phenyl, $-NO_2$, $-CN$, $-OR_{C-2}$, $-SR_{C-2}$, $-SOR_{C-2}$, $-SO_2R_{C-2}$, $-NR_{C-2}C(O)R_{C-3}$, $-NR_{C-2}C(O)R_{C-2}$, $-NR_{C-2}C(O)R_{C-4}$, $-N(R_{C-2})_2$, $-C(O)R_{C-2}$, $-C(O)_2R_{C-2}$, $-C(O)N(R_{C-2})_2$, $-SCN$, $-NR_{C-2}C(O)R_{C-2}$, $-S(O)N(R_{C-2})_2$, $-S(O)_2N(R_{C-2})_2$, $-NR_{C-2}S(O)_2R_{C-2}$, R_5 , or R_6 ;

Each R_{C-2} is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R_{C-5} , cycloalkyl substituted with 1 substituent selected from R_{C-5} , heterocycloalkyl substituted with 1 substituent selected from R_{C-5} , haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted phenyl;


Each R_{C-3} is independently H, alkyl, or substituted alkyl;

R_{C-4} is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, $-OH$, $-CN$, $-NH_2$, $-NH(alkyl)$, or $-N(alkyl)_2$;

R_{C-5} is $-CN$, $-CF_3$, $-NO_2$, $-OR_{C-6}$, $-SR_{C-6}$, $-N(R_{C-6})_2$, $-C(O)R_{C-6}$, $-SOR_{C-6}$, $-SO_2RR_{C-6}$, $-C(O)N(R_{C-6})_2$, $-NR_{C-6}C(O)R_{C-6}$, $-S(O)_2N(R_{C-6})_2$, or $-NR_{C-6}S(O)_2R_{C-6}$;

Each R_{C-6} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

wherein W is (D):



5

provided that the bond between the $-C(=X)-$ group and the W group may be attached at any available carbon atom within the D group as provided in R_{D-1} , R_{D-3} , and R_{D-4} ;

D^0 , D^1 , D^2 , and D^3 are N or $C(R_{D-1})$ provided that up to one of D^0 , D^1 , D^2 , or D^3 is N and the others are $C(R_{D-1})$, further provided that when the core molecule is attached at D^2 and D^0 or D^1 is N, D^3 is C(H), and further provided that there is only one attachment to the core molecule;

$D^4---D^5---D^6$ is selected from $N(R_{D-2})-C(R_{D-3})=C(R_{D-3})$, $N=C(R_{D-3})-C(R_{D-4})_2$, $C(R_{D-3})=C(R_{D-3})-N(R_{D-2})$, $C(R_{D-3})_2-N(R_{D-2})-C(R_{D-3})_2$, $C(R_{D-4})_2-C(R_{D-3})=N$, $N(R_{D-2})-C(R_{D-3})_2-C(R_{D-3})_2$, $C(R_{D-3})_2-C(R_{D-3})_2-N(R_{D-2})$, $O-C(R_{D-3})=C(R_{D-3})$, $O-C(R_{D-3})_2-C(R_{D-3})_2$, $C(R_{D-3})_2-O-C(R_{D-3})_2$, $C(R_{D-3})=C(R_{D-3})-O$, $C(R_{D-3})_2-C(R_{D-3})_2-O$, $S-C(R_{D-3})=C(R_{D-3})$, $S-C(R_{D-3})_2-C(R_{D-3})_2$, $C(R_{D-3})_2-S-C(R_{D-3})_2$, $C(R_{D-3})=C(R_{D-3})-S$, or $C(R_{D-3})_2-C(R_{D-3})_2-S$;

provided that when C(X) is attached to W at D^2 and D^6 is O, N(R_{D-2}), or S, D^4---D^5 is not $CH=CH$;

and further provided that when C(X) is attached to W at D^2 and D^4 is O, N(R_{D-2}), or S, D^5---D^6 is not $CH=CH$;

Each R_{D-1} is independently H, F, Br, I, Cl, -CN, -CF₃, -OR_{D-5}, -SR_{D-5}, -N(R_{D-5})₂, or a bond to $-C(X)-$ provided that only one of R_{D-1} , R_{D-3} , and R_{D-4} is said bond;

Each R_{D-2} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5 , or R_6 ;

Each R_{D-3} is independently H, F, Br, Cl, I, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, heterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, -CN, -NO₂,

-OR_{D-10}, -C(O)N(R_{D-11})₂, -NR_{D-10}COR_{D-12}, -N(R_{D-10})₂, -SR_{D-10}, -S(O)₂R_{D-10},
-C(O)R_{D-12}, -CO₂R_{D-10}, aryl, R₅, R₆, a bond to -C(X)- provided that only one of R_{D-1},
R_{D-3}, and R_{D-4} is said bond;

Each R_{D-4} is independently H, F, Br, Cl, I, alkyl, substituted alkyl, haloalkyl,
5 alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl,
heterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, -CN, -NO₂,
-OR_{D-10}, -C(O)N(R_{D-11})₂, -NR_{D-10}COR_{D-12}, -N(R_{D-11})₂, -SR_{D-10}, -CO₂R_{D-10}, aryl, R₅,
R₆, a bond to -C(X)- provided that only one of R_{D-1}, R_{D-3}, and R_{D-4} is said bond;

Each R_{D-5} is independently H, C₁₋₃ alkyl, or C₂₋₄ alkenyl;

10 D⁷ is O, S, or N(R_{D-2});


D⁸ and D⁹ are C(R_{D-1}), provided that when the molecule is attached to the
phenyl moiety at D⁹, D⁸ is CH;

Each R_{D-10} is H, alkyl, cycloalkyl, haloalkyl, substituted phenyl, or substituted
naphthyl;

15 Each R_{D-11} is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl
substituted with 1 substituent selected from R₁₃, cycloalkyl substituted with 1
substituent selected from R₁₃, heterocycloalkyl substituted with 1 substituent selected
from R₁₃, haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted
phenyl;

20 R_{D-12} is H, alkyl, substituted alkyl, cycloalkyl, haloalkyl, heterocycloalkyl,
substituted heterocycloalkyl, substituted phenyl, or substituted naphthyl;

wherein W is (E):



25 E⁰ is CH or N;

R_{E-0} is H, F, Cl, Br, I, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl,
haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, substituted
alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted
heterocycloalkyl, aryl, R₅, R₆, -OR_{E-3}, -OR_{E-4}, -SR_{E-3}, -SR_{E-5}, -N(R_{E-3})₂, -NR_{E-3}R_{E-6},
30 -N(R_{E-6})₂, -C(O)R_{E-3}, -CN, -C(O)N(R_{E-3})₂, -NR_{E-3}C(O)R_{E-3}, -S(O)R_{E-3}, -S(O)R_{E-5},

$-\text{OS}(\text{O})_2\text{R}_{\text{E}-3}$, $-\text{NR}_{\text{E}-3}\text{S}(\text{O})_2\text{R}_{\text{E}-3}$, $-\text{NO}_2$, or $-\text{N}(\text{H})\text{C}(\text{O})\text{N}(\text{H})\text{R}_{\text{E}-3}$;

E^1 is O, $\text{CR}_{\text{E}-1-1}$, or $\text{C}(\text{R}_{\text{E}-1-1})_2$, provided that when E^1 is $\text{CR}_{\text{E}-1-1}$, one $\text{R}_{\text{E}-1}$ is a bond to $\text{CR}_{\text{E}-1-1}$, and further provided that at least one of E^1 or E^2 is O;

Each $\text{R}_{\text{E}-1-1}$ is independently H, F, Br, Cl, CN, alkyl, haloalkyl, substituted alkyl, alkynyl, cycloalkyl, $-\text{OR}_{\text{E}}$, or $-\text{N}(\text{R}_{\text{E}})_2$, provided that at least one $\text{R}_{\text{E}-1-1}$ is H when E^1 is $\text{C}(\text{R}_{\text{E}-1-1})_2$;

Each $\text{R}_{\text{E}-1}$ is independently H, alkyl, substituted alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, or a bond to E^1 provided that E^1 is $\text{CR}_{\text{E}-1-1}$;

E^2 is O, $\text{CR}_{\text{E}-2-2}$, or $\text{C}(\text{R}_{\text{E}-2-2})_2$, provided that when E^2 is $\text{CR}_{\text{E}-2-2}$, one $\text{R}_{\text{E}-2}$ is a bond to $\text{CR}_{\text{E}-2-2}$, and further provided that at least one of E^1 or E^2 is O;

Each $\text{R}_{\text{E}-2-2}$ is independently H, F, Br, Cl, CN, alkyl, haloalkyl, substituted alkyl, alkynyl, cycloalkyl, $-\text{OR}_{\text{E}}$, or $-\text{N}(\text{R}_{\text{E}})_2$; provided that at least one $\text{R}_{\text{E}-2-2}$ is H when E^2 is $\text{C}(\text{R}_{\text{E}-2-2})_2$;

Each $\text{R}_{\text{E}-2}$ is independently H, alkyl, substituted alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, or a bond to E^2 provided that E^2 is $\text{CR}_{\text{E}-2-2}$;

Each R_{E} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;


Each $\text{R}_{\text{E}-3}$ is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5 , R_6 , phenyl, or phenyl having 1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I or substituted phenyl;

$\text{R}_{\text{E}-4}$ is H, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5 , R_6 , phenyl, or substituted phenyl;

Each $\text{R}_{\text{E}-5}$ is independently H, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5 , or R_6 ;

Each $\text{R}_{\text{E}-6}$ is independently alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5 , R_6 , phenyl, or phenyl having 1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I;

wherein W is (F):



F^0 is C(H) wherein $F^1 \cdots F^2 \cdots F^3$ is selected from O-C(R_{F-2})=N,

- 5 O-C(R_{F-3})(R_{F-2})-N(R_{F-4}), O-C(R_{F-3})(R_{F-2})-S, O-N=C(R_{F-3}), O-C(R_{F-2})(R_{F-3})-O,
 S-C(R_{F-2})=N, S-C(R_{F-3})(R_{F-2})-N(R_{F-4}), S-N=C(R_{F-3}), N=C(R_{F-2})-O, N=C(R_{F-2})-S,
 N=C(R_{F-2})-N(R_{F-4}), N(R_{F-4})-N=C(R_{F-3}), N(R_{F-4})-C(R_{F-3})(R_{F-2})-O,
 N(R_{F-4})-C(R_{F-3})(R_{F-2})-S, N(R_{F-4})-C(R_{F-3})(R_{F-2})-N(R_{F-4}), C(R_{F-3})₂-O-N(R_{F-4}),
 C(R_{F-3})₂-N(R_{F-4})-O, C(R_{F-3})₂-N(R_{F-4})-S, C(R_{F-3})=N-O, C(R_{F-3})=N-S,
 10 C(R_{F-3})=N-N(R_{F-4}), or C(R_{F-3})₂-C(R_{F-2})(R_{F-3})-C(R_{F-3})₂;

F^0 is N wherein $F^1 \cdots F^2 \cdots F^3$ is selected from O-C(R_{F-2})=N,

- O-C(R_{F-3})(R_{F-2})-N(R_{F-4}), O-C(R_{F-3})(R_{F-2})-S, O-N=C(R_{F-3}) O-C(R_{F-2})(R_{F-3})-O,
 S-C(R_{F-2})=N, S-C(R_{F-3})(R_{F-2})-N(R_{F-4}), S-N=C(R_{F-3}), N=C(R_{F-2})-O, N=C(R_{F-2})-S,
 N=C(R_{F-2})-N(R_{F-4}), N(R_{F-4})-N=C(R_{F-3}), N(R_{F-4})-C(R_{F-3})(R_{F-2})-O,
 15 N(R_{F-4})-C(R_{F-3})(R_{F-2})-S, N(R_{F-4})-C(R_{F-3})(R_{F-2})-N(R_{F-4}), C(R_{F-3})₂-O-N(R_{F-4}),
 C(R_{F-3})₂-N(R_{F-4})-O, C(R_{F-3})₂-N(R_{F-4})-S, C(R_{F-3})=N-O, C(R_{F-3})=N-S,
 C(R_{F-3})=N-N(R_{F-4}), C(R_{F-3})=C(R_{F-2})-C(R_{F-3})₂, or C(R_{F-3})₂-C(R_{F-2})(R_{F-3})-C(R_{F-3})₂;

F^4 is N(R_{F-7}), O, or S;

R_{F-1} is H, F, Cl, Br, I, -CN, -CF₃, -OR_{F-8}, -SR_{F-8}, or -N(R_{F-8})₂;

- 20 R_{F-2} is H, F, alkyl, haloalkyl, substituted alkyl, lactam heterocycloalkyl,
 phenoxy, substituted phenoxy, R₅, R₆, -N(R_{F-4})-aryl,
 -N(R_{F-4})-substituted phenyl, -N(R_{F-4})-substituted naphthyl, -O-substituted phenyl,
 -O-substituted naphthyl, -S-substituted phenyl, -S-substituted naphthyl, or alkyl
 substituted on the ω carbon with R_{F-9};

- 25 R_{F-3} is H, F, Br, Cl, I, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted
 alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, heterocycloalkyl,
 substituted heterocycloalkyl, lactam heterocycloalkyl, -CN, -NO₂, -OR_{F-8},
 -C(O)N(R_{F-8})₂, -NHR_{F-8}, -NR_{F-8}COR_{F-8}, -N(R_{F-8})₂, -SR_{F-8}, -C(O)R_{F-8},
 -CO₂R_{F-8}, aryl, R₅, or R₆;


- 30 R_{F-4} is H, or alkyl;

R_{F-7} is H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I;

R_{F-8} is H, alkyl, substituted alkyl, cycloalkyl, haloalkyl, heterocycloalkyl, substituted heterocycloalkyl, substituted phenyl, or substituted naphthyl;

R_{F-9} is aryl, R_5 , or R_6 ;

wherein W is (G):



G^1 is N or CH;

Each G^2 is N or $C(R_{G-1})$, provided that no more than one G^2 is N;

Each R_{G-1} is independently H, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, -CN, -NO₂, F, Br, Cl, I, -C(O)N(R_{G-3})₂, -N(R_{G-3})₂, -SR_{G-6}, -S(O)₂R_{G-6}, -OR_{G-6}, -C(O)R_{G-6}, -CO₂R_{G-6}, aryl, R_5 , R_6 , or two R_{G-1} on adjacent carbon atoms may combine for W to be a 6-5-6 fused-tricyclic-heteroaromatic-ring system optionally substituted on the newly formed ring where valency allows with 1-2 substituents independently selected from F, Cl, Br, I, and R_{G-2} ;

R_{G-2} is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, -OR_{G-8}, -SR_{G-8}, -S(O)₂R_{G-8}, -S(O)R_{G-8}, -OS(O)₂R_{G-8}, -N(R_{G-8})₂, -C(O)R_{G-8}, -C(S)R_{G-8}, -C(O)OR_{G-8}, -CN, -C(O)N(R_{G-8})₂, -NR_{G-8}C(O)R_{G-8}, -S(O)₂N(R_{G-8})₂, -NR_{G-8}S(O)₂R_{G-8}, -NO₂, -N(R_{G-8})C(O)N(R_{G-8})₂, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, phenyl having 0-4 substituents independently selected from F, Cl, Br, I and R_{G-7} , naphthyl, or naphthyl having 0-4 substituents independently selected from F, Cl, Br, I, or R_{G-7} ;

provided that when G^2 adjacent to the bridge N is $C(R_{G-1})$ and the other G^2 are CH, that R_{G-1} is other than H, F, Cl, I, alkyl, substituted alkyl or alkynyl;

Each R_{G-3} is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R_{G-4} , cycloalkyl substituted with 1

substituent selected from R_{G-4} , heterocycloalkyl substituted with 1 substituent selected from R_{G-4} , haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted phenyl;

R_{G-4} is $-OR_{G-5}$, $-SR_{G-5}$, $-N(R_{G-5})_2$, $-C(O)R_{G-5}$, $-SOR_{G-5}$, $-SO_2R_{G-5}$,
 5 $-C(O)N(R_{G-5})_2$, $-CN$, $-CF_3$, $-NR_{G-5}C(O)R_{G-5}$, $-S(O)_2N(R_{G-5})_2$, $-NR_{G-5}S(O)_2R_{G-5}$, or
 $-NO_2$;


Each R_{G-5} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

R_{G-6} is H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl,
 10 substituted cycloalkyl, phenyl, or phenyl having 0-4 substituents independently
 selected from F, Cl, Br, I, and R_{G-7} ;

R_{G-7} is alkyl, substituted alkyl, haloalkyl, $-OR_{G-5}$, $-CN$, $-NO_2$, $-N(R_{G-3})_2$;

Each R_{G-8} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl,
 halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl,
 15 substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently
 selected from F, Cl, Br, I, or R_{G-7} ;

wherein W is (H)



20 H' is N or CH;

Each R_{H-1} is independently F, Cl, Br, I, $-CN$, $-NO_2$, alkyl, haloalkyl,
 substituted alkyl, alkenyl, haloalkenyl, substituted alkenyl, alkynyl, haloalkynyl,
 substituted alkynyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl,
 heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, lactam
 25 heterocycloalkyl, aryl, R_5 , R_6 , $-OR_8$, $-SR_8$, $-SOR_8$, $-SO_2R_8$, $-SCN$, $-S(O)N(R_8)_2$,
 $-S(O)_2N(R_8)_2$, $-C(O)R_8$, $-C(O)_2R_8$, $-C(O)N(R_8)_2$, $C(R_8)=N-OR_8$, $-NC(O)R_5$,
 $-NC(O)R_{H-3}$, $-NC(O)R_6$, $-N(R_8)_2$, $-NR_8C(O)R_8$, $-NR_8S(O)_2R_8$, or two R_{H-1} on adjacent
 carbon atoms may fuse to form a 6-membered ring to give a 5-6 fused, bicyclic moiety
 where the 6-membered ring is optionally substituted with 1-3 substituents selected
 30 from R_{H-2} ;

m_H is 0, 1, or 2;

R_{H-2} is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, $-OR_{H-3}$, $-SR_{H-3}$, $-S(O)_2R_{H-3}$, $-S(O)R_{H-3}$, $-OS(O)_2R_{H-3}$, $-N(R_{H-3})_2$, $-C(O)R_{H-3}$, $-C(S)R_{H-3}$, $-C(O)OR_{H-3}$, $-CN$, $-C(O)N(R_{H-3})_2$, $-NR_{H-3}C(O)R_{H-3}$, $-S(O)_2N(R_{H-3})_2$, $-NR_{H-3}S(O)_2R_{H-3}$, $-NO_2$, $-N(R_{H-3})C(O)N(R_{H-3})_2$, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, phenyl having 0-4 substituents independently selected from F, Cl, Br, I and R_7 , naphthyl, naphthyl having 0-4 substituents independently selected from F, Cl, Br, I, or R_7 , or two R_{H-2} on adjacent carbon atoms may combine to form a three-ring-fused-5-6-6 system optionally substituted with up to 3 substituents independently selected from Br, Cl, F, I, $-CN$, $-NO_2$, $-CF_3$, $-N(R_{H-3})_2$, $-N(R_{H-3})C(O)R_{H-3}$, alkyl, alkenyl, and alkynyl;

Each R_{H-3} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R_7 ;

or pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof.

5. The method of claim 4, wherein X is O, R_2 is absent, R_{2-3} , R_3 , and R_4 are each H, and W is 4-chlorobenz-1-yl; dibenzo[b,d]thiophene-2-yl; isoquinoline-3-yl; furo[2,3-c]pyridine-5-yl; 1,3-benzodioxole-5-yl; 2,3-dihydro-1,4-benzodioxine-6-yl; 1,3-benzoxazole-5-yl; thieno[2,3-c]pyridine-5-yl; thieno[3,2-c]pyridine-6-yl; [1]benzothieno[3,2-c]pyridine-3-yl; 1,3-benzothiazole-6-yl; thieno[3,4-c]pyridine-6-yl; 2,3-dihydro-1-benzofuran-5-yl; 1-benzofuran-5-yl; furo[3,2-c]pyridine-6-yl; [1]benzothieno[2,3-c]pyridine-3-yl; dibenzo[b,d]furan-2-yl; 1-benzofuran-6-yl; 2-naphthyl; 1H-indole-6-yl; pyrrolo[1,2-c]pyrimidine-3-yl; 1-benzothiophene-5-yl; 1-benzothiophene-5-yl; 1-benzothiophene-6-yl; pyrrolo[1,2-a]pyrazine-3-yl; 1H-indole-6-yl; pyrazino[1,2-a]indole-3-yl; 1,3-benzothiazole-6-yl; [1]benzofuro[2,3-c]pyridine-3-yl; [1]benzofuro[2,3-c]pyridine-3-yl; 2H-chromene-6-yl; indolizine-6-yl; and [1,3]dioxolo[4,5-c]pyridine-6-yl; any of which is optionally substituted as allowed in claim 4.

6. The method of claim 5, wherein the monoamine reuptake inhibitor is desipramine (Norpramin), nortriptyline, atomoxetine (Strattera), reboxetine, fluoxetine (Prozac), tomoxetine, bupropion (Wellbutrin), and modafonil (Provigil), provided that the monoamine reuptake inhibitor is present, and wherein the
 5 psychostimulant is methylphenidate (Ritalin), dextroamphetamine (Dexedrine), amphetamine (Adderall), and pemoline, provided that the psychostimulant is present.

7. The method of claim 5, wherein the psychostimulant is methylphenidate (Ritalin), dextroamphetamine (Dexedrine), amphetamine (Adderall), and pemoline.

10

8. The method of claim 4, wherein the agonist is:

- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]dibenzo[b,d]thiophene-2-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]isoquinoline-3-carboxamide;
 15 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzodioxole-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methylfuro[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2,3-dihydro-1,4-benzodioxine-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
 20 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]isoquinoline-3-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzoxazole-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1,3-benzoxazole-5-carboxamide;
 25 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropylfuro[2,3-c]pyridine-5-carboxamide;
 30 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
 5-{[(2R)-7-azoniabicyclo[2.2.1]hept-2-ylamino]carbonyl}-3-ethylfuro[2,3-c]pyridin-6-ium dichloride;

- 5- {[(2R)-7-azoniabicyclo[2.2.1]hept-2-ylamino]carbonyl}-3-isopropylfuro[2,3-c]pyridin-6-ium dichloride;
- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]furo[2,3-c]pyridine-5-carboxamide;
- N-1-azabicyclo[2.2.2]oct-3-yl[1]benzothieno[3,2-c]pyridine-3-carboxamide;
- 5 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;
- N-1-azabicyclo[2.2.2]oct-3-ylfuro[2,3-c]pyridine-5-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,4-c]pyridine-6-carboxamide;
- N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
- 10 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2,3-dihydro-1-benzofuran-5-carboxamide;
- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;
- 15 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide;
- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-ethylfuro[2,3-c]pyridine-5-carboxamide;
- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-isopropylfuro[2,3-c]pyridine-5-carboxamide;
- 20 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;
- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-chlorofuro[2,3-c]pyridine-5-carboxamide;
- N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-4-chlorobenzamide;
- 25 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,4-c]pyridine-6-carboxamide;
- N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]dibenzo[b,d]thiophene-2-carboxamide;
- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzofuran-5-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1]benzothieno[2,3-c]pyridine-3-carboxamide;
- N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1]benzothieno[2,3-c]pyridine-3-
- 30 carboxamide;
- N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-carboxamide;
- N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]dibenzo[b,d]furan-2-carboxamide;
- N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;

- N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromofuro[2,3-c]pyridine-5-
 5 carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;
 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
 10 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1H-indole-6-carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]thieno[2,3-c]pyridine-5-
 carboxamide;
 15 3-methyl-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-
 carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,2-c]pyridine-6-
 carboxamide;
 20 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-
 carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-5-carboxamide;
 25 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1,3-benzodioxole-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromo-1-benzofuran-5-carboxamide;
 30 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromo-1-benzofuran-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromothieno[2,3-c]pyridine-5-
 carboxamide;

- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzothiophene-5-carboxamide;
 N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methyl-1-benzofuran-5-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1-benzofuran-5-carboxamide;
 5 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-6-carboxamide;
 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-6-carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-6-carboxamide;
 10 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzothiophene-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-methyl-1H-indole-6-carboxamide;
 N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropyl-1-benzofuran-5-carboxamide;
 15 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-isopropyl-1-benzofuran-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1H-indazole-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-5-carboxamide;
 20 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1-benzofuran-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrazino[1,2-a]indole-3-carboxamide;
 3-bromo-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
 25 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-methoxy-2-naphthamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromo-1-benzofuran-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1]benzofuro[2,3-c]pyridine-3-carboxamide;
 30 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1]benzofuro[2,3-c]pyridine-3-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynyl-1-benzofuran-5-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynyl-1-benzofuran-5-carboxamide;

- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2H-chromene-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-1,3-benzodioxole-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;
 5 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynylfuro[2,3-c]pyridine-5-carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]indolizine-6-carboxamide;
 10 2-amino-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-8-methoxy-2-naphthamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]indolizine-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;
 15 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyano-1-benzofuran-5-carboxamide;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethyl-2,3-dihydro-1,4-benzodioxine-6-
 20 carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-hydroxy-2-naphthamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-chloroisoquinoline-3-carboxamide;
 25 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethyl-2,3-dihydro-1,4-benzodioxine-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethyl-2,3-dihydro-1,4-benzodioxine-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-methylisoquinoline-3-carboxamide;
 30 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-methylisoquinoline-3-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyanofuro[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide; and

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]dibenzo[b,d]furan-2-carboxamide, provided that the full agonist is a free base or a pharmaceutically acceptable salt thereof.

9. The method of claim 8, wherein the monoamine reuptake inhibitor is
5 desipramine (Norpramin), nortriptyline, atomoxetine (Strattera), reboxetine, fluoxetine (Prozac), tomoxetine, bupropion (Wellbutrin), and modafonil (Provigil), provided that the monoamine reuptake inhibitor is present, and wherein the psychostimulant is methylphenidate (Ritalin), dextroamphetamine (Dexedrine), amphetamine (Adderall), and pemoline, provided that the psychostimulant is present.
- 10
10. The method of claim 9, wherein the monoamine reuptake inhibitor is desipramine (Norpramin), nortriptyline, atomoxetine (Strattera), reboxetine, fluoxetine (Prozac), tomoxetine, bupropion (Wellbutrin), and modafonil (Provigil).
- 15
11. The method of claim 8, wherein the psychostimulant is methylphenidate (Ritalin), dextroamphetamine (Dexedrine), amphetamine (Adderall), and pemoline.
12. The method of claim 1, wherein the mammal is a human.
- 20
13. The method of claim 12, wherein the $\alpha 7$ nAChR full agonist is administered with the monoamine reuptake inhibitor.
14. The method of claim 12, wherein the $\alpha 7$ nAChR full agonist is administered with the monoamine reuptake inhibitor and the psychostimulant.
- 25
15. The method of claim 12, wherein the $\alpha 7$ nAChR full agonist is administered with the psychostimulant.
16. A composition comprising an effective amount of an $\alpha 7$ nAChR full agonist
30 and an effective amount of a monoamine reuptake inhibitor or an effective amount of a psychostimulant, or an effective amount of a monoamine reuptake inhibitor and an effective amount of a psychostimulant.

17. The composition of claim 16, wherein the monoamine reuptake inhibitor is desipramine (Norpramin), nortriptyline, atomoxetine (Strattera), reboxetine, fluoxetine (Prozac), tomoxetine, bupropion (Wellbutrin), and modafonil (Provigil), provided that the monoamine reuptake inhibitor is present, and wherein the
 5 psychostimulant is methylphenidate (Ritalin), dextroamphetamine (Dexedrine), amphetamine (Adderall), and pemoline, provided that the psychostimulant is present.

18. The composition of claim 17, wherein the monoamine reuptake inhibitor is desipramine (Norpramin), nortriptyline, atomoxetine (Strattera), reboxetine,
 10 fluoxetine (Prozac), tomoxetine, bupropion (Wellbutrin), and modafonil (Provigil).


19. The composition of claim 16, wherein the psychostimulant is methylphenidate (Ritalin), dextroamphetamine (Dexedrine), amphetamine (Adderall), and pemoline.

20. The composition of claim 16, wherein the $\alpha 7$ nAChR full agonist is a compound of formula I:



Formula I

wherein Azabicyclo is



wherein X is O, or S;

R₀ is H, lower alkyl, substituted lower alkyl, or lower haloalkyl;

Each R₁ is H, alkyl, cycloalkyl, haloalkyl, substituted phenyl, or substituted
 25 naphthyl;

Each R_2 is independently F, Cl, Br, I, alkyl, substituted alkyl, haloalkyl, cycloalkyl, aryl, or R_2 is absent provided that k_{1-2} , k_{1-6} , k_2 , k_5 , k_6 , or k_7 is 0;

k_{1-2} is 0 or 1;

k_{1-6} is 0 or 1, provided that the sum of k_{1-2} and k_{1-6} is one;

5 k_2 is 0 or 1;

k_5 is 0, 1, or 2;

k_6 is 0, 1, or 2;


k_7 is 0 or 1;

R_{2-3} is H, F, Cl, Br, I, alkyl, haloalkyl, substituted alkyl, cycloalkyl, or aryl;


10 Each R_3 is independently H, alkyl, or substituted alkyl;

R_4 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, -NH₂, -NH(alkyl), or -N(alkyl)₂;


R_5 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of -O-, =N-,
15 -N(R_{10})-, and -S-, and having 0-1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I, or R_5 is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring and having the formula



20 wherein L_1 is O, S, or NR_{10} ,



wherein L is CR_{12} or N, L_2 and L_3 are independently selected from CR_{12} , $C(R_{12})_2$, O, S, N, or NR_{10} , provided that both L_2 and L_3 are not simultaneously O, simultaneously S, or simultaneously O and S, or



25

wherein L is CR_{12} or N, and L_2 and L_3 are independently selected from CR_{12} , O, S, N, or NR_{10} , and each 9-membered fused-ring moiety having 0-1 substituent selected from R_9 and further having 0-3 substituent(s) independently selected from F, Cl, Br, or I,

wherein the R₅ moiety attaches to other substituents as defined in formula I at any position as valency allows;

R₆ is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from R₉ and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R₆ is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R₉ and 0-3 substituent(s) independently selected from F, Cl, Br, or I, wherein the R₆ moiety attaches to other substituents as defined in formula I at any position as valency allows;

R₇ is alkyl, substituted alkyl, haloalkyl, -OR₁₁, -CN, -NO₂, -N(R₈)₂;

Each R₈ is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R₁₃, cycloalkyl substituted with 1 substituent selected from R₁₃, heterocycloalkyl substituted with 1 substituent selected from R₁₃, haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted phenyl;

R₉ is alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, -OR₁₄, -SR₁₄, -N(R₁₄)₂, -C(O)R₁₄, -C(O)N(R₁₄)₂, -CN, -NR₁₄C(O)R₁₄, -S(O)₂N(R₁₄)₂, -NR₁₄S(O)₂R₁₄, -NO₂, alkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R₁₃, cycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R₁₃, or heterocycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R₁₃;

R₁₀ is H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 1 substituent selected from R₇ and further having 0-3 substituents independently selected from F, Cl, Br, or I;

Each R₁₁ is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

Each R₁₂ is independently H, F, Cl, Br, I, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -CN, -NO₂, -OR₁₄, -SR₁₄, -N(R₁₄)₂,


-C(O)R₁₄, -C(O)N(R₁₄)₂, -NR₁₄C(O)R₁₄, -S(O)₂N(R₁₄)₂, -NR₁₄S(O)₂RR₁₄, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that where valency allows the fused-ring moiety has 0-1 substituent selected from

5 alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -OR₁₄, -SR₁₄, -N(R₁₄)₂, -C(O)R₁₄, -NO₂, -C(O)N(R₁₄)₂, -CN, -NR₁₄C(O)R₁₄, -S(O)₂N(R₁₄)₂, or -NR₁₄S(O)₂R₁₄, and further provided that the fused-ring moiety has 0-3 substituent(s) selected from F, Cl, Br, or I;

10 R₁₃ is -OR₁₄, -SR₁₄, -N(R₁₄)₂, -C(O)R₁₄, -C(O)N(R₁₄)₂, -CN, -CF₃, -NR₁₄C(O)R₁₄, -S(O)₂N(R₁₄)₂, -NR₁₄S(O)₂R₁₄, or -NO₂;

Each R₁₄ is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

15 wherein W is (A):



wherein R_{A-1a} is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted

20 heterocycloalkyl, aryl, -R₅, R₆, -OR_{A-3}, -OR_{A-4}, -SR_{A-3}, F, Cl, Br, I, -N(R_{A-3})₂, -N(R_{A-5})₂, -C(O)R_{A-3}, -C(O)R_{A-5}, -CN, -C(O)N(R_{A-3})₂, -C(O)N(R_{A-6})₂, -NR_{A-3}C(O)R_{A-3}, -S(O)R_{A-3}, -OS(O)₂R_{A-3}, -NR_{A-3}S(O)₂R_{A-3}, -NO₂, and -N(H)C(O)N(H)R_{A-3};

R_{A-1b} is -O-R_{A-3}, -S-R_{A-3}, -S(O)-R_{A-3}, -C(O)-R_{A-7}, and alkyl substituted on the

25 ω carbon with R_{A-7};

Each R_{A-3} is independently selected from H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, halo-

heterocycloalkyl, substituted heterocycloalkyl, R₅, R₆, phenyl, or substituted phenyl;

R_{A-4} is selected from cycloalkyl, halocycloalkyl, substituted cycloalkyl,


30 heterocycloalkyl, haloheterocycloalkyl, or substituted heterocycloalkyl;

Each R_{A-5} is independently selected from cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5 , R_6 , phenyl, or substituted phenyl;

Each R_{A-6} is independently selected from alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, halo-
 5 heterocycloalkyl, substituted heterocycloalkyl, R_5 , R_6 , phenyl, or substituted phenyl;

R_{A-7} is selected from aryl, R_5 , or R_6 ;

wherein W is (B):



10

wherein B^0 is -O-, -S-, or -N(R_{B-0})-;

B^1 and B^2 are independently selected from =N-, or =C(R_{B-1})-;

B^3 is =N-, or =CH-, provided that when both B^1 and B^2 are =C(R_{B-1})- and B^3 is =CH-, only one =C(R_{B-1})- can be =CH-, and further provided that when B^0 is -O-, B^2
 15 is =C(R_{B-1})- and B^3 is =C(H)-, B^1 cannot be =N-,

R_{B-0} is H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, limited substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, or aryl, and provided that when B is (B-2) and B^3 is =N- and B^0 is N(R_{B-0}), R_{B-0} cannot be phenyl or substituted phenyl;

20 R_{B-1} is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, limited substituted alkyl, limited substituted alkenyl, limited substituted alkynyl, aryl, -OR_{B-2}, -OR_{B-3}, -SR_{B-2}, -SR_{B-3}, F, Cl, Br, I, -N(R_{B-2})₂,
 25 -N(R_{B-3})₂, -C(O)R_{B-2}, -C(O)R_{B-3}, -C(O)N(R_{B-2})₂, -C(O)N(R_{B-3})₂, -CN, -NR_{B-2}C(O)R_{B-4}, -S(O)₂N(R_{B-2})₂, -OS(O)₂R_{B-4}, -S(O)₂R_{B-2}, -S(O)₂R_{B-3}, -NR_{B-2}S(O)₂R_{B-2}, -N(H)C(O)N(H)R_{B-2}, -NO₂, R_5 , and R_6 ;

Each R_{B-2} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl,
 30 substituted heterocycloalkyl, R_5 , R_6 , phenyl, or substituted phenyl;

Each R_{B-3} is independently H, alkyl, haloalkyl, limited substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl;

R_{B-4} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl,
5 halocycloalkyl, or haloheterocycloalkyl;

wherein W is (C):

(C) is a six-membered heterocyclic ring system having 1-2 nitrogen atoms or a
10 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms
within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six-
six-fused-ring system, and further having 1-2 substituents independently selected
from R_{C-1} ;

Each R_{C-1} is independently H, F, Cl, Br, I, alkyl, haloalkyl, substituted alkyl,
alkenyl, haloalkenyl, substituted alkenyl, alkynyl, haloalkynyl, substituted alkynyl,
15 cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl,
haloheterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl,
substituted phenyl, $-\text{NO}_2$, $-\text{CN}$, $-\text{OR}_{C-2}$, $-\text{SR}_{C-2}$, $-\text{SOR}_{C-2}$, $-\text{SO}_2\text{R}_{C-2}$, $-\text{NR}_{C-2}\text{C}(\text{O})\text{R}_{C-3}$,
 $-\text{NR}_{C-2}\text{C}(\text{O})\text{R}_{C-2}$, $-\text{NR}_{C-2}\text{C}(\text{O})\text{R}_{C-4}$, $-\text{N}(\text{R}_{C-2})_2$, $-\text{C}(\text{O})\text{R}_{C-2}$, $-\text{C}(\text{O})_2\text{R}_{C-2}$, $-\text{C}(\text{O})\text{N}(\text{R}_{C-2})_2$,
 $-\text{SCN}$, $-\text{NR}_{C-2}\text{C}(\text{O})\text{R}_{C-2}$, $-\text{S}(\text{O})\text{N}(\text{R}_{C-2})_2$, $-\text{S}(\text{O})_2\text{N}(\text{R}_{C-2})_2$, $-\text{NR}_{C-2}\text{S}(\text{O})_2\text{R}_{C-2}$, R_5 , or R_6 ;

20 Each R_{C-2} is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl
substituted with 1 substituent selected from R_{C-5} , cycloalkyl substituted with 1
substituent selected from R_{C-5} , heterocycloalkyl substituted with 1 substituent selected
from R_{C-5} , haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted
phenyl;


25 Each R_{C-3} is independently H, alkyl, or substituted alkyl;

R_{C-4} is H, alkyl, an amino protecting group, or an alkyl group having 1-3
substituents selected from F, Cl, Br, I, $-\text{OH}$, $-\text{CN}$, $-\text{NH}_2$, $-\text{NH}(\text{alkyl})$, or $-\text{N}(\text{alkyl})_2$;

R_{C-5} is $-\text{CN}$, $-\text{CF}_3$, $-\text{NO}_2$, $-\text{OR}_{C-6}$, $-\text{SR}_{C-6}$, $-\text{N}(\text{R}_{C-6})_2$, $-\text{C}(\text{O})\text{R}_{C-6}$, $-\text{SOR}_{C-6}$,
 $-\text{SO}_2\text{RR}_{C-6}$, $-\text{C}(\text{O})\text{N}(\text{R}_{C-6})_2$, $-\text{NR}_{C-6}\text{C}(\text{O})\text{R}_{C-6}$, $-\text{S}(\text{O})_2\text{N}(\text{R}_{C-6})_2$, or $-\text{NR}_{C-6}\text{S}(\text{O})_2\text{R}_{C-6}$;

30 Each R_{C-6} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl,
halocycloalkyl, or haloheterocycloalkyl;

wherein W is (D):



provided that the bond between the $-C(=X)-$ group and the W group may be attached at any available carbon atom within the D group as provided in R_{D-1} , R_{D-3} , and R_{D-4} ;

D^0 , D^1 , D^2 , and D^3 are N or $C(R_{D-1})$ provided that up to one of D^0 , D^1 , D^2 , or D^3 is N and the others are $C(R_{D-1})$, further provided that when the core molecule is attached at D^2 and D^0 or D^1 is N, D^3 is $C(H)$, and further provided that there is only one attachment to the core molecule;

$D^4---D^5---D^6$ is selected from $N(R_{D-2})-C(R_{D-3})=C(R_{D-3})$, $N=C(R_{D-3})-C(R_{D-4})_2$, $C(R_{D-3})=C(R_{D-3})-N(R_{D-2})$, $C(R_{D-3})_2-N(R_{D-2})-C(R_{D-3})_2$, $C(R_{D-4})_2-C(R_{D-3})=N$, $N(R_{D-2})-C(R_{D-3})_2-C(R_{D-3})_2$, $C(R_{D-3})_2-C(R_{D-3})_2-N(R_{D-2})$, $O-C(R_{D-3})=C(R_{D-3})$, $O-C(R_{D-3})_2-C(R_{D-3})_2$, $C(R_{D-3})_2-O-C(R_{D-3})_2$, $C(R_{D-3})=C(R_{D-3})-O$, $C(R_{D-3})_2-C(R_{D-3})_2-O$, $S-C(R_{D-3})=C(R_{D-3})$, $S-C(R_{D-3})_2-C(R_{D-3})_2$, $C(R_{D-3})_2-S-C(R_{D-3})_2$, $C(R_{D-3})=C(R_{D-3})-S$, or $C(R_{D-3})_2-C(R_{D-3})_2-S$;

provided that when $C(X)$ is attached to W at D^2 and D^6 is O, $N(R_{D-2})$, or S, D^4---D^5 is not $CH=CH$;

and further provided that when $C(X)$ is attached to W at D^2 and D^4 is O, $N(R_{D-2})$, or S, D^5---D^6 is not $CH=CH$;

Each R_{D-1} is independently H, F, Br, I, Cl, $-CN$, $-CF_3$, $-OR_{D-5}$, $-SR_{D-5}$, $-N(R_{D-5})_2$, or a bond to $-C(X)-$ provided that only one of R_{D-1} , R_{D-3} , and R_{D-4} is said bond;

Each R_{D-2} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5 , or R_6 ;

Each R_{D-3} is independently H, F, Br, Cl, I, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, heterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, $-CN$, $-NO_2$, $-OR_{D-10}$, $-C(O)N(R_{D-11})_2$, $-NR_{D-10}COR_{D-12}$, $-N(R_{D-10})_2$, $-SR_{D-10}$, $-S(O)_2R_{D-10}$, $-C(O)R_{D-12}$, $-CO_2R_{D-10}$, aryl, R_5 , R_6 , a bond to $-C(X)-$ provided that only one of R_{D-1} , R_{D-3} , and R_{D-4} is said bond;

Each R_{D-4} is independently H, F, Br, Cl, I, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, heterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, -CN, -NO₂, -OR_{D-10}, -C(O)N(R_{D-11})₂, -NR_{D-10}COR_{D-12}, -N(R_{D-11})₂, -SR_{D-10}, -CO₂R_{D-10}, aryl, R₅,
 5 R₆, a bond to -C(X)- provided that only one of R_{D-1}, R_{D-3}, and R_{D-4} is said bond;

Each R_{D-5} is independently H, C₁₋₃ alkyl, or C₂₋₄ alkenyl;

D⁷ is O, S, or N(R_{D-2});


D⁸ and D⁹ are C(R_{D-1}), provided that when the molecule is attached to the phenyl moiety at D⁹, D⁸ is CH;

10 Each R_{D-10} is H, alkyl, cycloalkyl, haloalkyl, substituted phenyl, or substituted naphthyl;

Each R_{D-11} is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R₁₃, cycloalkyl substituted with 1 substituent selected from R₁₃, heterocycloalkyl substituted with 1 substituent selected
 15 from R₁₃, haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted phenyl;

R_{D-12} is H, alkyl, substituted alkyl, cycloalkyl, haloalkyl, heterocycloalkyl, substituted heterocycloalkyl, substituted phenyl, or substituted naphthyl;

20 wherein W is (E):



E⁰ is CH or N;

R_{E-0} is H, F, Cl, Br, I, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, substituted
 25 alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, aryl, R₅, R₆, -OR_{E-3}, -OR_{E-4}, -SR_{E-3}, -SR_{E-5}, -N(R_{E-3})₂, -NR_{E-3}R_{E-6}, -N(R_{E-6})₂, -C(O)R_{E-3}, -CN, -C(O)N(R_{E-3})₂, -NR_{E-3}C(O)R_{E-3}, -S(O)R_{E-3}, -S(O)R_{E-5}, -OS(O)₂R_{E-3}, -NR_{E-3}S(O)₂R_{E-3}, -NO₂, or -N(H)C(O)N(H)R_{E-3};

E¹ is O, CR_{E-1-1}, or C(R_{E-1-1})₂, provided that when E¹ is CR_{E-1-1}, one R_{E-1} is a
 30 bond to CR_{E-1-1}, and further provided that at least one of E¹ or E² is O;

Each R_{E-1-1} is independently H, F, Br, Cl, CN, alkyl, haloalkyl, substituted alkyl, alkynyl, cycloalkyl, $-OR_E$, or $-N(R_E)_2$, provided that at least one R_{E-1-1} is H when E^1 is $C(R_{E-1-1})_2$;

Each R_{E-1} is independently H, alkyl, substituted alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, or a bond to E^1 provided that E^1 is CR_{E-1-1} ;

E^2 is O, CR_{E-2-2} , or $C(R_{E-2-2})_2$, provided that when E^2 is CR_{E-2-2} , one R_{E-2} is a bond to CR_{E-2-2} , and further provided that at least one of E^1 or E^2 is O;

Each R_{E-2-2} is independently H, F, Br, Cl, CN, alkyl, haloalkyl, substituted alkyl, alkynyl, cycloalkyl, $-OR_E$, or $-N(R_E)_2$, provided that at least one R_{E-2-2} is H when E^2 is $C(R_{E-2-2})_2$;

Each R_{E-2} is independently H, alkyl, substituted alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, or a bond to E^2 provided that E^2 is CR_{E-2-2} ;

Each R_E is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;


Each R_{E-3} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5 , R_6 , phenyl, or phenyl having 1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I or substituted phenyl;

R_{E-4} is H, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5 , R_6 , phenyl, or substituted phenyl;

Each R_{E-5} is independently H, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5 , or R_6 ;

Each R_{E-6} is independently alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5 , R_6 , phenyl, or phenyl having 1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I;

wherein W is (F):



F^0 is C(H) wherein $F^1 \text{---} F^2 \text{---} F^3$ is selected from O-C(R_{F-2})=N,
 O-C(R_{F-3})(R_{F-2})-N(R_{F-4}), O-C(R_{F-3})(R_{F-2})-S, O-N=C(R_{F-3}), O-C(R_{F-2})(R_{F-3})-O,
 S-C(R_{F-2})=N, S-C(R_{F-3})(R_{F-2})-N(R_{F-4}), S-N=C(R_{F-3}), N=C(R_{F-2})-O, N=C(R_{F-2})-S,
 5 N=C(R_{F-2})-N(R_{F-4}), N(R_{F-4})-N=C(R_{F-3}), N(R_{F-4})-C(R_{F-3})(R_{F-2})-O,
 N(R_{F-4})-C(R_{F-3})(R_{F-2})-S, N(R_{F-4})-C(R_{F-3})(R_{F-2})-N(R_{F-4}), C(R_{F-3})₂-O-N(R_{F-4}),
 C(R_{F-3})₂-N(R_{F-4})-O, C(R_{F-3})₂-N(R_{F-4})-S, C(R_{F-3})=N-O, C(R_{F-3})=N-S,
 C(R_{F-3})=N-N(R_{F-4}), or C(R_{F-3})₂-C(R_{F-2})(R_{F-3})-C(R_{F-3})₂;

F^0 is N wherein $F^1 \text{---} F^2 \text{---} F^3$ is selected from O-C(R_{F-2})=N,
 10 O-C(R_{F-3})(R_{F-2})-N(R_{F-4}), O-C(R_{F-3})(R_{F-2})-S, O-N=C(R_{F-3}), O-C(R_{F-2})(R_{F-3})-O,
 S-C(R_{F-2})=N, S-C(R_{F-3})(R_{F-2})-N(R_{F-4}), S-N=C(R_{F-3}), N=C(R_{F-2})-O, N=C(R_{F-2})-S,
 N=C(R_{F-2})-N(R_{F-4}), N(R_{F-4})-N=C(R_{F-3}), N(R_{F-4})-C(R_{F-3})(R_{F-2})-O,
 N(R_{F-4})-C(R_{F-3})(R_{F-2})-S, N(R_{F-4})-C(R_{F-3})(R_{F-2})-N(R_{F-4}), C(R_{F-3})₂-O-N(R_{F-4}),
 C(R_{F-3})₂-N(R_{F-4})-O, C(R_{F-3})₂-N(R_{F-4})-S, C(R_{F-3})=N-O, C(R_{F-3})=N-S,
 15 C(R_{F-3})=N-N(R_{F-4}), C(R_{F-3})=C(R_{F-2})-C(R_{F-3})₂, or C(R_{F-3})₂-C(R_{F-2})(R_{F-3})-C(R_{F-3})₂;

F^4 is N(R_{F-7}), O, or S;

R_{F-1} is H, F, Cl, Br, I, -CN, -CF₃, -OR_{F-8}, -SR_{F-8}, or -N(R_{F-8})₂;

R_{F-2} is H, F, alkyl, haloalkyl, substituted alkyl, lactam heterocycloalkyl,
 phenoxy, substituted phenoxy, R₅, R₆, -N(R_{F-4})-aryl,

20 -N(R_{F-4})-substituted phenyl, -N(R_{F-4})-substituted naphthyl, -O-substituted phenyl,
 -O-substituted naphthyl, -S-substituted phenyl, -S-substituted naphthyl, or alkyl
 substituted on the ω carbon with R_{F-9};

R_{F-3} is H, F, Br, Cl, I, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted
 alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, heterocycloalkyl,
 25 substituted heterocycloalkyl, lactam heterocycloalkyl, -CN, -NO₂, -OR_{F-8},
 -C(O)N(R_{F-8})₂, -NHR_{F-8}, -NR_{F-8}COR_{F-8}, -N(R_{F-8})₂, -SR_{F-8}, -C(O)R_{F-8},
 -CO₂R_{F-8}, aryl, R₅, or R₆;


R_{F-4} is H, or alkyl;

R_{F-7} is H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I;

R_{F-8} is H, alkyl, substituted alkyl, cycloalkyl, haloalkyl, heterocycloalkyl, substituted heterocycloalkyl, substituted phenyl, or substituted naphthyl;

R_{F-9} is aryl, R_5 , or R_6 ;

wherein W is (G):



G^1 is N or CH;

Each G^2 is N or $C(R_{G-1})$, provided that no more than one G^2 is N;

Each R_{G-1} is independently H, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, -CN, -NO₂, F, Br, Cl, I, -C(O)N(R_{G-3})₂, -N(R_{G-3})₂, -SR_{G-6}, -S(O)₂R_{G-6}, -OR_{G-6}, -C(O)R_{G-6}, -CO₂R_{G-6}, aryl, R_5 , R_6 , or two R_{G-1} on adjacent carbon atoms may combine for W to be a 6-5-6 fused-tricyclic-heteroaromatic-ring system optionally substituted on the newly formed ring where valency allows with 1-2 substituents independently selected from F, Cl, Br, I, and R_{G-2} ;

R_{G-2} is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, -OR_{G-8}, -SR_{G-8}, -S(O)₂R_{G-8}, -S(O)R_{G-8}, -OS(O)₂R_{G-8}, -N(R_{G-8})₂, -C(O)R_{G-8}, -C(S)R_{G-8}, -C(O)OR_{G-8}, -CN, -C(O)N(R_{G-8})₂, -NR_{G-8}C(O)R_{G-8}, -S(O)₂N(R_{G-8})₂, -NR_{G-8}S(O)₂R_{G-8}, -NO₂, -N(R_{G-8})C(O)N(R_{G-8})₂, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, phenyl having 0-4 substituents independently selected from F, Cl, Br, I and R_{G-7} , naphthyl, or naphthyl having 0-4 substituents independently selected from F, Cl, Br, I, or R_{G-7} ;

provided that when G^2 adjacent to the bridge N is $C(R_{G-1})$ and the other G^2 are CH, that R_{G-1} is other than H, F, Cl, I, alkyl, substituted alkyl or alkynyl;

Each R_{G-3} is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R_{G-4} , cycloalkyl substituted with 1

substituent selected from R_{G-4} , heterocycloalkyl substituted with 1 substituent selected from R_{G-4} , haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted phenyl;

R_{G-4} is $-OR_{G-5}$, $-SR_{G-5}$, $-N(R_{G-5})_2$, $-C(O)R_{G-5}$, $-SOR_{G-5}$, $-SO_2R_{G-5}$,
 5 $-C(O)N(R_{G-5})_2$, $-CN$, $-CF_3$, $-NR_{G-5}C(O)R_{G-5}$, $-S(O)_2N(R_{G-5})_2$, $-NR_{G-5}S(O)_2R_{G-5}$, or
 $-NO_2$;


Each R_{G-5} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

R_{G-6} is H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl,
 10 substituted cycloalkyl, phenyl, or phenyl having 0-4 substituents independently
 selected from F, Cl, Br, I, and R_{G-7} ;

R_{G-7} is alkyl, substituted alkyl, haloalkyl, $-OR_{G-5}$, $-CN$, $-NO_2$, $-N(R_{G-3})_2$;

Each R_{G-8} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl,
 halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl,
 15 substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently
 selected from F, Cl, Br, I, or R_{G-7} ;

wherein W is (H)



20 H' is N or CH;

Each R_{H-1} is independently F, Cl, Br, I, $-CN$, $-NO_2$, alkyl, haloalkyl,
 substituted alkyl, alkenyl, haloalkenyl, substituted alkenyl, alkynyl, haloalkynyl,
 substituted alkynyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl,
 heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, lactam
 25 heterocycloalkyl, aryl, R_5 , R_6 , $-OR_8$, $-SR_8$, $-SOR_8$, $-SO_2R_8$, $-SCN$, $-S(O)N(R_8)_2$,
 $-S(O)_2N(R_8)_2$, $-C(O)R_8$, $-C(O)_2R_8$, $-C(O)N(R_8)_2$, $C(R_8)=N-OR_8$, $-NC(O)R_5$,
 $-NC(O)R_{H-3}$, $-NC(O)R_6$, $-N(R_8)_2$, $-NR_8C(O)R_8$, $-NR_8S(O)_2R_8$, or two R_{H-1} on adjacent
 carbon atoms may fuse to form a 6-membered ring to give a 5-6 fused, bicyclic moiety
 where the 6-membered ring is optionally substituted with 1-3 substituents selected
 30 from R_{H-2} ;

m_H is 0, 1, or 2;

R_{H-2} is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, $-OR_{H-3}$, $-SR_{H-3}$, $-S(O)_2R_{H-3}$, $-S(O)R_{H-3}$, $-OS(O)_2R_{H-3}$, $-N(R_{H-3})_2$, $-C(O)R_{H-3}$, $-C(S)R_{H-3}$, $-C(O)OR_{H-3}$, $-CN$, $-C(O)N(R_{H-3})_2$, $-NR_{H-3}C(O)R_{H-3}$, $-S(O)_2N(R_{H-3})_2$, $-NR_{H-3}S(O)_2R_{H-3}$, $-NO_2$,
 5 $-N(R_{H-3})C(O)N(R_{H-3})_2$, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, phenyl having 0-4 substituents independently selected from F, Cl, Br, I and R_7 , naphthyl, naphthyl having 0-4 substituents independently selected from F, Cl, Br, I, or R_7 , or two R_{H-2} on adjacent carbon atoms may combine to form a three-ring-fused-5-
 10 6-6 system optionally substituted with up to 3 substituents independently selected from Br, Cl, F, I, $-CN$, $-NO_2$, $-CF_3$, $-N(R_{H-3})_2$, $-N(R_{H-3})C(O)R_{H-3}$, alkyl, alkenyl, and alkynyl;

Each R_{H-3} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl,
 15 substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R_7 ;

or pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof.

20 21. The composition of claim 20, wherein X is O, R_2 is absent, R_{2-3} , R_3 , and R_4 are each H, and W is 4-chlorobenz-1-yl; dibenzo[b,d]thiophene-2-yl; isoquinoline-3-yl; furo[2,3-c]pyridine-5-yl; 1,3-benzodioxole-5-yl; 2,3-dihydro-1,4-benzodioxine-6-yl; 1,3-benzoxazole-5-yl; thieno[2,3-c]pyridine-5-yl; thieno[3,2-c]pyridine-6-yl; [1]benzothieno[3,2-c]pyridine-3-yl; 1,3-benzothiazole-6-yl; thieno[3,4-c]pyridine-6-
 25 yl; 2,3-dihydro-1-benzofuran-5-yl; 1-benzofuran-5-yl; furo[3,2-c]pyridine-6-yl; [1]benzothieno[2,3-c]pyridine-3-yl; dibenzo[b,d]furan-2-yl; 1-benzofuran-6-yl; 2-naphthyl; 1H-indole-6-yl; pyrrolo[1,2-c]pyrimidine-3-yl; 1-benzothiophene-5-yl; 1-benzothiophene-5-yl; 1-benzothiophene-6-yl; pyrrolo[1,2-a]pyrazine-3-yl; 1H-indole-6-yl; pyrazino[1,2-a]indole-3-yl; 1,3-benzothiazole-6-yl; [1]benzofuro[2,3-c]pyridine-
 30 3-yl; [1]benzofuro[2,3-c]pyridine-3-yl; 2H-chromene-6-yl; indolizine-6-yl; and [1,3]dioxolo[4,5-c]pyridine-6-yl; any of which is optionally substituted as allowed in claim 20.

22. The composition of claim 21, wherein the agonist is:

- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]dibenzo[b,d]thiophene-2-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]isoquinoline-3-carboxamide;
 5 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzodioxole-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methylfuro[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2,3-dihydro-1,4-benzodioxine-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
 10 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]isoquinoline-3-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzoxazole-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1,3-benzoxazole-5-carboxamide;
 15 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropylfuro[2,3-c]pyridine-5-carboxamide;
 20 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
 5-{[(2R)-7-azoniabicyclo[2.2.1]hept-2-ylamino]carbonyl}-3-ethylfuro[2,3-c]pyridin-6-ium dichloride;
 5-{[(2R)-7-azoniabicyclo[2.2.1]hept-2-ylamino]carbonyl}-3-isopropylfuro[2,3-c]pyridin-6-ium dichloride;
 25 c]pyridin-6-ium dichloride;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]furo[2,3-c]pyridine-5-carboxamide;
 N-1-azabicyclo[2.2.2]oct-3-yl[1]benzothieno[3,2-c]pyridine-3-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;
 30 N-1-azabicyclo[2.2.2]oct-3-ylfuro[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,4-c]pyridine-6-carboxamide;
 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;

- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2,3-dihydro-1-benzofuran-5-carboxamide;
- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide;
- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-ethylfuro[2,3-c]pyridine-5-carboxamide;
- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-isopropylfuro[2,3-c]pyridine-5-
- 10 carboxamide;
- N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;
- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-chlorofuro[2,3-c]pyridine-5-carboxamide;
- N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
- 15 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-4-chlorobenzamide;
- N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,4-c]pyridine-6-carboxamide;
- N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]dibenzo[b,d]thiophene-2-carboxamide;
- N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzofuran-5-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1]benzothieno[2,3-c]pyridine-3-carboxamide;
- 20 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1]benzothieno[2,3-c]pyridine-3-carboxamide;
- N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-carboxamide;
- N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]dibenzo[b,d]furan-2-carboxamide;
- N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
- 25 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-5-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;
- 30 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;
- N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;
- N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;

- N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1H-indole-6-carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]thieno[2,3-c]pyridine-5-
 5 carboxamide;
 3-methyl-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-
 carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,2-c]pyridine-6-
 10 carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-
 carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;
 15 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-5-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1,3-benzodioxole-5-carboxamide;
 20 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromo-1-benzofuran-5-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromo-1-benzofuran-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromothieno[2,3-c]pyridine-5-
 carboxamide;
 25 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzothiophene-5-carboxamide;
 N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methyl-1-benzofuran-5-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1-benzofuran-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-6-carboxamide;
 30 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-6-carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-6-carboxamide;

- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzothiophene-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-methyl-1H-indole-6-carboxamide;
 N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;
 5 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropyl-1-benzofuran-5-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-isopropyl-1-benzofuran-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1H-indazole-6-carboxamide;
 10 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-5-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1-benzofuran-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrazino[1,2-a]indole-3-carboxamide;
 3-bromo-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
 15 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-methoxy-2-naphthamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromo-1-benzofuran-6-carboxamide;
 20 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1]benzofuro[2,3-c]pyridine-3-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1]benzofuro[2,3-c]pyridine-3-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynyl-1-benzofuran-5-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynyl-1-benzofuran-5-carboxamide;
 25 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2H-chromene-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-1,3-benzodioxole-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynylfuro[2,3-c]pyridine-5-carboxamide;
 30 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]indolizine-6-carboxamide;

- 2-amino-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-8-methoxy-2-naphthamide;
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]indolizine-6-carboxamide;
 5 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1,3]dioxolo[4,5-c]pyridine-6-
 carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyano-1-benzofuran-5-carboxamide;
 N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;
 10 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethyl-2,3-dihydro-1,4-benzodioxine-6-
 carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-hydroxy-2-naphthamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylfuro[2,3-c]pyridine-5-
 carboxamide;
 15 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-chloroisoquinoline-3-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethyl-2,3-dihydro-1,4-benzodioxine-6-
 carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethyl-2,3-dihydro-1,4-benzodioxine-6-
 carboxamide;
 20 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-methylisoquinoline-3-carboxamide;
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-methylisoquinoline-3-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyanofuro[2,3-c]pyridine-5-carboxamide;
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide; and
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]dibenzo[b,d]furan-2-carboxamide, provided that
 25 the full agonist is a free base or a pharmaceutically acceptable salt thereof.

23. The composition of claim 22, wherein the monoamine reuptake inhibitor is
 desipramine (Norpramin), nortriptyline, atomoxetine (Strattera), reboxetine,
 fluoxetine (Prozac), tomoxetine, bupropion (Wellbutrin), and modafonil (Provigil),
 30 provided that the monoamine reuptake inhibitor is present, and wherein the
 psychostimulant is methylphenidate (Ritalin), dextroamphetamine (Dexedrine),
 amphetamine (Adderall), and pemoline, provided that the psychostimulant is present.

24. The composition of claim 22, wherein the psychostimulant is methylphenidate (Ritalin), dextroamphetamine (Dexedrine), amphetamine (Adderall), and pemoline.